摘要
目的观察稳定期老年慢性阻塞性肺疾病(COPD)患者长期吸入可必特气雾剂(异丙托溴胺和沙丁胺醇)后,分别测定对可必特、异丙托溴胺及沙丁胺醇的反应性。方法18例老年稳定期COPD患者吸入可必特气雾剂,每次2喷,3次/d,连续治疗12周,并在治疗前后分别应用可必特、异丙托溴胺及沙丁胺醇气雾剂作为支气管舒张剂行支气管舒张试验,在用药前后测定1s用力呼气容积(FEV1.0)及FEV1.0改善率(△FEV1.0)。结果患者在治疗后吸入可必特的△FEV1.0比治疗前下降(P<0.05),同样在治疗后吸入沙丁胺醇的△FEV1.0比治疗前下降(P<0.01),而吸入异丙托溴胺在治疗前后FEV1.0的改善不明显(P>0.05);在治疗前患者吸入可必特的△FEV1.0要比吸入沙丁胺醇及异丙托溴胺高(P<0.01),在治疗后患者吸入可必特后的△FEV1.0仍高于吸入沙丁胺醇(P<0.01),但与吸入异丙托溴胺相比,差异无统计学意义。结论老年稳定期COPD患者长期联用异丙托溴胺与沙丁胺醇,仍可造成其对沙丁胺醇的反应性低下,建议不要长期联用,采用胆碱能拮抗剂治疗老年COPD患者是一理想途径。
Objective Observing stable-phased old patients of chronic obstructive pulmonary disease(COPD) to respond to combivent, ipratropium bromide or salbutamol respectively after long-term inhalation of the combivent(ie,ipratropium bromide/ salbutamol).Methods Eighteen stable-phased old patients of chronic obstructive pulmonary disease inhaled combivent aerosol( 2 puffs of ipratropium bromide/salbutamol ter in die).Pretherapy and post-treatment saw the patients receiving the test of bronchodilation with combivent, ipratropium bromide and salbutamol respectively,and checking FEV1. 0 and its improvement rate (△FEV1.0). Results △FEV1.0 of post-treatment was lower than that of pretherapy(P<0.05)when they inhaled combivent, and the result was the same(P<0.01) when the patients inhaled salbutamol,△FEV1.0 didn′t change in pretherapy and post-treatment when the patients inhaled ipratropium bromide (P>0.05),in pretherapy △FEV1. 0 of inhaled combivent was higher than that of inhaled ipratropium bromide or salbutamol (P<0.01),in post-treatment △FEV1. 0 of inhaled combivent was higher than that of inhaled salbutamol (P<0.01),but the difference wasn′t significant between combivent and ipratropium bromide.Conclusion Long-term combinative use of ipratropium bromide and salbutamol to aged stable COPD will decrease the responsiveness of patient to salbutamol.So we suggest long-term combined inhalation of ipratropium bromide and salbutamol is not a good idea, curing stable-phased old patients of COPD with cholinergic antagonist,ipratropium bromide, is a good choice.
出处
《中国药物与临床》
CAS
2005年第5期360-362,共3页
Chinese Remedies & Clinics